Biocon Finds a New Partner for its Biosimilar Insulin Analogues in Mylan
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 2 (Table of Contents)
Published: 26 Feb-2013
DOI: 10.3833/pdr.v2013.i2.1901 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Mylan has formed a global collaboration with the Indian biotech Biocon to develop and commercialise biosimilar versions of three insulin analogues: Sanofi’s Lantus® (glargine), Eli Lilly’s Humalog® (lispro) and Novo Nordisk’s NovoLog® (aspart)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS